Last update 20 Jun 2024

Gallium Dotatate Ga-68

Last update 20 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms

[ga-68] Dotatate, Gallium Ga 68 Dotatate, Netspot

Target

SSTR

Mechanism

SSTR modulators(Somatostatin receptor modulators), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Neuroendocrine TumorsGastro-Enteropancreatic Neuroendocrine TumorEstrogen receptor positive breast cancer+ [1]

Inactive Indication-

Originator Organization

Advanced Accelerator Applications SA

Active Organization

Hoag Memorial Hospital Presbyterian, Inc.

Rayzebio, Inc.Startup

HTA Co., Ltd.

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (01 Jun 2016),

Neuroendocrine Tumors

RegulationOrphan Drug (US)

Structure

Molecular FormulaC65H87N14O19S2.Ga

InChIKeyXBJPSVQFCQFGDC-WSCOIBMGSA-K

CAS Registry1027785-90-5

Boost your research with our XDC technology data.

view full example data

Gene Sequence

Sequence Code 19728

Clinical Trials associated with Gallium Dotatate Ga-68

NCT04298541 / Not yet recruitingPhase 2IIT

SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

The goal of this study is to propose the first direct comparison of Ga-68-DOTATATE PET/CT or PET/MR and Ga-68-DOTATOC PET/CT in patients with meningioma.

Start Date01 May 2024

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

CTR20240013 / RecruitingPhase 3

评价镓[68Ga]多特安肽注射液 PET/CT 对神经内分泌瘤（NETs）的诊断效能、药代动力学和安全性及比较镥[177Lu]氧奥曲肽注射液与长效奥曲肽在不可切除或转移性、进展性、分化良好（G1 和 G2）且生长抑素受体阳性的成人胃肠胰神经内分泌瘤患者中的安全性和有效性的诊疗一体化的Ⅲ期临床研究

[Translation] A phase III clinical study to evaluate the diagnostic efficacy, pharmacokinetics and safety of gallium [68Ga] dotetan injection PET/CT for neuroendocrine tumors (NETs) and to compare the safety and efficacy of lutetium [177Lu] oxyoctreotide injection with long-acting octreotide in adult patients with unresectable or metastatic, progressive, well-differentiated (G1 and G2) somatostatin receptor-positive gastrointestinal pancreatic neuroendocrine tumors

主要目的：基于相对于真实性标准的受试者水平的灵敏度和特异度，评价镓[68Ga]多特安肽注射液 PET/CT 对 NETs 的诊断效能。次要目的：评价镓[68Ga]多特安肽注射液作为 PET/CT 检查的示踪剂在中国人群中的安全性；评价镓[68Ga]多特安肽注射液作为 PET/CT 检查的示踪剂在中国人群中的药代动力学（PK）及辐射剂量学。

[Translation]

Primary objective: To evaluate the diagnostic efficacy of gallium [68Ga] dotetan injection PET/CT for NETs based on the sensitivity and specificity at the subject level relative to the authenticity standard. Secondary objectives: To evaluate the safety of gallium [68Ga] dotetan injection as a tracer for PET/CT examination in the Chinese population; To evaluate the pharmacokinetics (PK) and radiation dosimetry of gallium [68Ga] dotetan injection as a tracer for PET/CT examination in the Chinese population.

Start Date05 Jan 2024

Sponsor / Collaborator

HTA Co., Ltd.

NCT05880394 / Active, not recruitingPhase 2IIT

Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.

Start Date10 Jan 2023

Sponsor / Collaborator

Hoag Memorial Hospital Presbyterian, Inc.

100 Clinical Results associated with Gallium Dotatate Ga-68

100 Translational Medicine associated with Gallium Dotatate Ga-68

100 Patents (Medical) associated with Gallium Dotatate Ga-68

175

Literatures (Medical) associated with Gallium Dotatate Ga-68

01 Mar 2024·Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Performance evaluation of Gallium-68 radiopharmaceuticals production using liquid target PETtrace 800 cyclotron

Article

Author: Mahamood, Mazurin ; Halib, Dzulieza ; Adawiyah, Rabiatul ; Aziz, Firdaus ; Ashhar, Zarif ; Mat Ail, Noratikah ; Md Safee, Zaitulhusna ; Jamal Harizan, Muhammad Ali Hazizi ; Ahmad Fadzil, Muhammad Fakhrurazi ; Abd Hamid, Mohd Hamdi Noor ; Ibarhim, Ummi Habibah ; Razali, Nor Idayu ; Said, Mohamad Aminudin ; Alek Amran, Arieffuddin ; Nik Afinde, Nik Muhammad Fitri

Due to increased demand, cyclotron has an expanding role in producing Gallium-68 (⁶⁸Ga) radiopharmaceuticals using solid and liquid targets. Though the liquid target produces lower end-of-bombardment activity compared to the solid target, our study presents the performance of ⁶⁸Ga radiopharmaceuticals production using the liquid target by evaluating the end-of-bombardment activity and the end-of-purification activity of [⁶⁸Ga]GaCl₃. We also present the effect of increasing irradiation time, which significantly improves the end-of-synthesis yield. From the result obtained, the end-of-bombardment activity produced was 4.48 GBq, and the [⁶⁸Ga]GaCl₃ end-of-purification activity produced was 2.51 GBq with below-limit metallic impurities. Increasing the irradiation time showed a significant increase in the end-of-synthesis activity from 1.33 GBq to 1.95 GBq for [⁶⁸Ga]Ga-PSMA-11 and from 1.13 GBq to 1.74 GBq for [⁶⁸Ga]Ga-DOTA-TATE. Based on the improvements made, the liquid target production of ⁶⁸Ga radiopharmaceuticals is feasible and reproducible to accommodate up to 5 patients per production. In addition, this work also discusses the issues encountered, together with the possible corrective and preventative measures.

European journal of nuclear medicine and molecular imaging

Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas

Article

Author: Liao, Zhihong ; He, Qiao ; Zhang, Bing ; Zhang, Zhengkun ; Zhang, Xiangsong ; Zhang, Yuying ; Zhang, Linqi ; Zha, Zhihao ; Long, Yali

PURPOSE:

To compare the detection ability of ⁶⁸Ga-labelled DOTA-l-Nal3-octreotide ([⁶⁸Ga]Ga-DOTA-NOC) and 6-[¹⁸F]fluoro-L-3,4-dihydroxyphenylalanine ([¹⁸F]DOPA) in patients with phaeochromocytomas and paragangliomas (PPGLs) of different origins and gene mutations, such as germline succinate dehydrogenase complex genes (SDHx).

METHODS:

Eighty-five patients with histopathologically confirmed PPGLs who underwent both [⁶⁸Ga]Ga-DOTA-NOC and [¹⁸F]DOPA PET/CT from March 2017 to June 2023 were enrolled in this retrospective study. For comparative analyses, PPGLs were classified as phaeochromocytoma (PCC), sympathetic paraganglioma (sPGL), and head/neck paraganglioma (HNPGL). Detection rates were analyzed on per-patient and per-lesion bases and compared using the Chi-square/Fischer's exact test.

RESULTS:

Among 85 patients with PPGLs (48 males; 43 years ± 17 [SD]), the patient-based detection rates of [⁶⁸Ga]Ga-DOTA-NOC and [¹⁸F]DOPA PET/CT were 87.1% (74/85) and 89.4% (76/85), respectively (p = 0.634), and the lesion-based detection rates were 80.8% (479/593) and 71.2% (422/593), respectively (p < 0.001). Only one patient with a recurrent PCC presented double-negative imaging, while 66 patients exhibited double-positive imaging. The remaining patients were either [⁶⁸Ga]Ga-DOTA-NOC-negative/[¹⁸F]DOPA-positive (n = 10) or [⁶⁸Ga]Ga-DOTA-NOC-positive/[¹⁸F]DOPA-negative (n = 8). In subgroup analyses, [⁶⁸Ga]Ga-DOTA-NOC PET/CT detected significantly more metastases of sPGL (91.1%, 236/259) and SDHx-related PPGL (89.6%, 86/96) than [¹⁸F]DOPA PET/CT (48.6%[126/259] and 50.0%[48/96], respectively; both p < 0.001). However, [¹⁸F]DOPA showed significantly higher detection rates of PCC in both primary/recurrent and metastatic lesions (94.3%[50/53] vs. 62.3%[33/53] and 87.9%[174/198] vs. 69.2%[137/198], respectively; both p < 0.001). Regarding metastases in different organs, [⁶⁸Ga]Ga-DOTA-NOC PET/CT detected more lesions than [¹⁸F]DOPA PET/CT in bone (96.2%[176/183] vs. 66.1%[121/183]; p < 0.001) and lymph nodes (82.0%[73/89] vs. 53.9%[48/89]; p < 0.001) but less lesions in peritoneum (20%[4/20] vs. 100%[20/20]; p < 0.001).

CONCLUSION:

[⁶⁸Ga]Ga-DOTA-NOC and [¹⁸F]DOPA are complementary in diagnosing PPGL under the appropriate clinical setting. [⁶⁸Ga]Ga-DOTA-NOC should be considered as the ideal first-line tracer for detecting metastases of sPGL and SDHx-related tumours, whereas [¹⁸F]DOPA may be the optimal tracer for evaluating non-SDHx-related PCC, especially in detecting primary lesions and monitoring recurrence.

01 Jan 2024·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer

Article

Author: Lapa, Constantin ; Bundschuh, Ralph A ; Beck, Roswitha ; Viering, Oliver ; Dierks, Alexander ; Kircher, Malte ; Pfob, Christian H ; Wienand, Georgine ; Holzleitner, Nadine ; Günther, Thomas ; Wester, Hans-Jürgen

Because of the need for radiolabeled theranostics for the detection and treatment of medullary thyroid cancer (MTC), and the yet unresolved stability issues of minigastrin analogs targeting the cholecystokinin-2 receptor (CCK-2R), our aim was to address in vivo stability, our motivation being to develop and evaluate DOTA-CCK-66 (DOTA-γ-glu-PEG₃-Trp-(N-Me)Nle-Asp-1-Nal-NH₂, PEG: polyethylene glycol) and DOTA-CCK-66.2 (DOTA-glu-PEG₃-Trp-(N-Me)Nle-Asp-1-Nal-NH₂), both derived from DOTA-MGS5 (DOTA-glu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH₂), and clinically translate [⁶⁸Ga]Ga-DOTA-CCK-66. Methods: ⁶⁴Cu and ⁶⁷Ga labeling of DOTA-CCK-66, DOTA-CCK-66.2, and DOTA-MGS5 was performed at 90°C within 15 min (1.0 M NaOAc buffer, pH 5.5, and 2.5 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, respectively). ¹⁷⁷Lu labeling of these 3 compounds was performed at 90°C within 15 min (1.0 M NaOAc buffer, pH 5.5, 0.1 M sodium ascorbate). CCK-2R affinity of ^natGa/^natCu/^natLu-labeled DOTA-CCK-66, DOTA-CCK-66.2, and DOTA-MGS5 was examined on AR42J cells. The in vivo stability of ¹⁷⁷Lu-labeled DOTA-CCK-66 and DOTA-MGS5 was examined at 30 min after injection in CB17-SCID mice. Biodistribution studies at 1 h ([⁶⁷Ga]Ga-DOTA-CCK-66) and 24 h ([¹⁷⁷Lu]Lu-DOTA-CCK-66/DOTA-MGS5) after injection were performed on AR42J tumor-bearing CB17-SCID mice. In a translation to the human setting, [⁶⁸Ga]Ga-DOTA-CCK-66 was administered and whole-body PET/CT was acquired at 120 min after injection in 2 MTC patients. Results: Irrespective of the metal or radiometal used (copper, gallium, lutetium), high CCK-2R affinity (half-maximal inhibitory concentration, 3.6-6.0 nM) and favorable lipophilicity were determined. In vivo, increased numbers of intact peptide were found for [¹⁷⁷Lu]Lu-DOTA-CCK-66 compared with [¹⁷⁷Lu]Lu-DOTA-MGS5 in murine urine (23.7% ± 9.2% vs. 77.8% ± 2.3%). Overall tumor-to-background ratios were similar for both ¹⁷⁷Lu-labeled analogs. [⁶⁷Ga]Ga-DOTA-CCK-66 exhibited accumulation (percentage injected dose per gram) that was high in tumor (19.4 ± 3.5) and low in off-target areas (blood, 0.61 ± 0.07; liver, 0.31 ± 0.02; pancreas, 0.23 ± 0.07; stomach, 1.81 ± 0.19; kidney, 2.51 ± 0.49) at 1 h after injection. PET/CT examination in 2 MTC patients applying [⁶⁸Ga]Ga-DOTA-CCK-66 confirmed multiple metastases. Conclusion: Because of the high in vivo stability and favorable overall preclinical performance of [^nat/67Ga]Ga-/[^nat/177Lu]Lu-DOTA-CCK-66, a proof-of-concept clinical investigation of [⁶⁸Ga]Ga-DOTA-CCK-66 was completed. As several lesions could be identified and excellent biodistribution patterns were observed, further patient studies applying [⁶⁸Ga]Ga- and [¹⁷⁷Lu]Lu-DOTA-CCK-66 are warranted.

News (Medical) associated with Gallium Dotatate Ga-68

06 Jun 2024

·www.biopharmadive.com

Germany’s ITM raises $205M as radiopharma field booms

Dive Brief:Radiopharmaceutical drug developer ITM has raised 188 million euros, or about $205 million, to fund its development of the targeted radiation therapies for cancer.Announced by ITM Thursday, the financing is the latest evidence of the substantial investment flowing into the field of radiopharmaceuticals, which are designed to deliver a cancer-killing radioisotope directly into tumors while sparing nearby healthy tissue.ITM, short for Isotope Technologies Munich, has advanced a radiopharmaceutical drug for a type of gastrointestinal cancer into two Phase 3 studies that are estimated to complete this year and in 2027. Uniquely, ITM is also a supplier of radioisotopes, including the commonly used lutetium-177.Dive Insight:Thursdays funding comes almost exactly one year after ITM raised 255 million euros from the same group of investors, a syndicate that includes Temasek, BlackRock and the Qatar Investment Authority.In the 12 months since that June 2023 funding, four of ITMs radiopharma peers have been acquired in deals worth a combined $8.5 billion. Several others have struck research collaborations with large drugmakers like Eli Lilly and Roche. And hundreds of millions of dollars in investment have flown into new startups.Steffen Schuster, the longtime CEO of ITM, hasnt been surprised by the frenzy of activity. Hes expected as much since Novartis acquired the radiopharma company Endocyte five years ago, gaining a prostate cancer treatment it now sells as Pluvicto.We said as soon as Pluvicto is a blockbuster, big pharma will wake up and say, Hey, wait a minute, I missed the train, Schuster said in an interview.Pluvicto sales last year totaled $980 million and Novartis expects theyll eventually reach triple that sum each year. The success of Pluvicto and another radiopharma Novartis sells called Lutathera have helped convince other large companies that the drug class is an essential building block for their oncology pipelines. Bristol Myers spent $4.1 billion to buy RayzeBio; AstraZeneca paid $2 billion for Fusion Pharmaceuticals; and Eli Lilly bought Point Biopharma for $1.4 billion.The whole market has changed completely, Schuster said.The executive declined to comment on whether ITM has had discussions with larger firms, but said that its position supplying isotopes and developing drugs both gives it control and builds value.The bulk of the new funding will go toward ITMs pipeline, which is led by its gastrointestinal cancer drug ITM-11. Other treatments are in much earlier phases of testing, but involve a range of tumor types as well as radioisotopes.ITM-11 is aimed at the same target as Novartis Lutathera and uses the same isotope: lutetium-177. Schuster noted differences in its dosing intervals as well as in some of the treatments components, however.[The goal] is not just taking market share from Novartis, said Schuster. Its creating a larger market. There are so many patients who could get this treatment who dont get treatment.In addition to development, ITM currently manufactures and supplies lutetium-177 as well as an imaging radioisotope known as gallium-68. In January, the company said a new production site in Germany was ready for business and, several months prior, launched a joint venture with Canadian Nuclear Laboratories to produce actinium-225, another radioisotope that drugmakers are using.There are so many synergies between these two parts of the businesses, said Schuster.Along with Temasek, BlackRock and Qatar Investment Authority, investors Athos and Carbyne were involved in ITMs fundraising. Nextech, which participated in the June 2023 funding, was not among the named investors in Thursdays announcement. '

AcquisitionRadiation TherapyPhase 3

21 May 2024

·www.biospace.com

Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer

SPRINGFIELD, N.J., May 21, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced that they have entered into a collaboration and licensing-agreement with the Innsbruck Medical University (MUI), a leading European research institution to advance the development of novel radiopharmaceuticals. The agreement covers the clinical development of EVG321, a novel radioligand therapy (RLT) for small cell lung cancer (SCLC), targeting the cholecystokinin 2 receptor (CCK2R). RLTs have surged into the clinic and represent a rapidly expanding market. By combining the power of medical isotopes and the precision of targeted therapeutics, these types of medicines allow for cell-specific ablation of a tumor target, thereby localizing ionizing radiation to diseased tissues. CCK2R has been shown to be highly expressed in SCLC, and has the potential to facilitate robust, tumor-specific delivery. "We are very pleased to announce this new collaboration with the Medical University of Innsbruck," commented James Cook, CEO of Evergreen Theragnostics. "For several years, the research groups of Univ. Prof. Dr. Irene Virgolini and Priv. Doz. Dr. Elisabeth von Guggenberg in Innsbruck have established themselves as key innovators in the RLT-field, and we are excited to be working with them on one of their lead programs – this was an easy choice to make." He added: "Especially in the realm of small cell lung cancer, novel therapies are urgently needed, and we are confident that EVG321 has the potential to significantly improve outcomes for cancer patients in this indication." Univ. Prof. Dr. Irene Virgolini, Medical University of Innsbruck, said: "Evergreen Discovery is a pioneer in the field of radiopharmaceuticals, and their team is looking back on an impressive record in bringing novel medicines to patients. We are delighted to be collaborating with them. In conjunction with their subject matter expertise and proven ability to translate new radioligand therapies, it is their exceptional sense of urgency to bring novel drugs to patients in need, making them such valuable partners for us." Over the next months, Evergreen intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 (177Lu) EVG321 and Gallium-68 (68Ga) EVG321. If successful, EVG321 could offer new hope to patients with small cell lung cancer. About Evergreen Theragnostics, Inc. Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing, research, and clinical development. For more information, please visit . About Medical University of Innsbruck Medical University of Innsbruck has approximately 2,200 employees and around 3,400 students and, together with the University of Innsbruck, is the largest educational and research institution in western Austria and the regional university for Tyrol, Vorarlberg, South Tyrol and Liechtenstein. Medical University of Innsbruck is involved in numerous international educational and research programmes and networks. The research focuses on the areas Oncology, Neuroscience, Genetics, Epigenetics and Genomics as well as Infectious Diseases, Immunology & Organ and Tissue Repair. In addition to scientific research, Medical University of Innsbruck is also nationally and internationally very successful in the highly competitive field of research funding. For more information on Medical University of Innsbruck, please visit For further information, please contact: James Cook President & CEO james.cook@evergreentgn.com

License out/in

16 Apr 2024

·www.prnewswire.com

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

SPRINGFIELD, N.J., April 16, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing advances Evergreen's novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to meet growing client demand. "We have been advancing our discovery pipeline and are excited to take the next step in development," commented James Cook, CEO. "As we continue to work with the FDA on approval of our Ga-68 DOTATOC diagnostic kit, this new funding will enable us to rapidly progress our novel theragnostic pair, EVG-321, into clinical trials. In addition, our CDMO business is continuing to build momentum as we bring on new customers and expand our efforts with existing ones. We appreciate the trust given to us by our existing and new shareholders in advancing our priorities." "We have tracked Evergreen since the company's inception and are excited to partner with James and his team as they bring best- and first-in-class candidates into the clinic, broaden their top-tier radiopharma drug discovery efforts, prepare for commercial launch of their diagnostic product, and further capitalize on the highly specialized expertise required to build and run a radiopharma CDMO," said Patrick Lally, Partner at Petrichor. Stefano Buono, chairman of LIFTT and founder and former CEO of Advanced Accelerator Applications (AAA) noted, "the radioligand therapy industry is advancing rapidly. Our investment in Evergreen Theragnostics deepens our commitment to this exciting area with a company that is well-positioned to succeed." Evergreen has established a lean and experienced team of scientific, medical, commercial, and operational leaders and employees to continue to develop our capabilities. Over the next months, Evergreen will continue to plan for the launch of our diagnostic agent Octevy™, subject to approval by the FDA. Evergreen Discovery also intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 (177Lu) EVG-321 and Gallium-68 (68Ga) EVG-321, a novel radiopharmaceutical theragnostic pair, which, if successful, could offer new hope to patients with small cell lung cancer. About Evergreen Theragnostics, Inc. Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing and commercialization. For more information, please visit . About Petrichor Petrichor partners with world-class healthcare managers and businesses to provide customized investment structures and support. The Petrichor team has completed over 125 investments representing more than $6 billion in invested capital and has held over 55 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies. For more information on Petrichor, please see or contact the firm at [email protected]. About LIFTT LIFTT is an Italian Venture Capital operating in every industry with a focus on deep-tech. To date it has raised €103,7M and completed 50 investments in innovative start-ups. While generating value for its shareholders, LIFTT supports the creation of businesses, development, employment, and economic growth, through the implementation of an ethical and transparent governance model. To learn more, please visit For further information, please contact: James Cook President & CEO [email protected] SOURCE Evergreen Theragnostics, Inc.

100 Deals associated with Gallium Dotatate Ga-68

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuroendocrine Tumors	US	Advanced Accelerator Applications USA, Inc.	01 Jun 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 3	CN	HTA Co., Ltd.	05 Jan 2024
Estrogen receptor positive breast cancer	Phase 2	US	Hoag Memorial Hospital Presbyterian, Inc.	10 Jan 2023
Estrogen receptor positive breast cancer	Phase 2	US	Rayzebio, Inc.Startup	10 Jan 2023
Metastatic breast cancer	Phase 2	US	Rayzebio, Inc.Startup	10 Jan 2023
Metastatic breast cancer	Phase 2	US	Hoag Memorial Hospital Presbyterian, Inc.	10 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2024	Not Applicable	Neuroendocrine Tumors	-	Cu64-dotatate-PET/CT	beojgqbfmg(bqmsmbjemh) = dnovonugme esvlsmmakp (knwldqtyha ) View more	-	24 May 2024
ASCO2024	Not Applicable	Neuroendocrine Tumors	-	Ga68-dotatate-PET/CT	beojgqbfmg(bqmsmbjemh) = jvxqnwgazh esvlsmmakp (knwldqtyha ) View more	-	24 May 2024
ASCO_GI2023	Not Applicable	Apudoma	424	Ga68-DOTATE (Patients with well-differentiated NETs of GI and pancreatic origin)	iqzvsbhjpx(jocydutpvb) = iukgqnioke xavujhshaf (rdsjgknibq ) View more	-	24 Jan 2023
ASCO_GI2023	Not Applicable	Apudoma	424	Ga68-DOTATE (Patients with lung carcinoid)	bhfaqmkxyn(xwryzyvdep) = pmhragrflc lgyrtrzhli (dovguiguwu )	-	24 Jan 2023
NCT03549598 (CTgov)	Phase 4	Cardiac sarcoidosis	15	13NH3 PET/CT scan+18FDG PET/CT scan+68Ga-DOTATATE PET/CT	flkxriyfzv(nrmitqfaex) = mnitcmjiwh gxhgsybagl (ztixiecmyf, wsvklepnyx - gpicsfvdjm) View more	-	20 Oct 2020
NCT02546388 (CTgov)	Not Applicable	Cardiac sarcoidosis	17	Gallium-68 DOTATATE (Gallium-68 DOTATATE)	gsziqpcygk(sqbkrofwux) = gndjvuwfzy rbctlmigrv (mknksqvria, frftqbeyud - zjzsrovxjj) View more	-	25 Mar 2020
NCT02546388 (CTgov)	Not Applicable	Cardiac sarcoidosis	17	Indium-111 Pentreotide (Indium-111 Pentreotide (OctreoScan))	gsziqpcygk(sqbkrofwux) = vtnkxytwwo rbctlmigrv (mknksqvria, eemzghhoah - ejojdzacjr) View more	-	25 Mar 2020
NCT01967537 (CTgov)	Phase 2	Von Hippel-Lindau Disease \| Neuroendocrine Tumors	341	Radio-guided surgery+68Gallium DOTATATE	umgxmuudev(nzhyfecyik) = zalyheiotx nkgjtcnetw (ywacatryly, zqllivdeiu - ziwtwuiyef) View more	-	02 Apr 2019
ASCO_GI2019	Not Applicable	Neuroendocrine Tumors	101	Ga-68 Dotatate PET/CT	ihnrvolylv(nxdtkhkdgw) = qppgfazedg vszebpjzxg (jwzixunuct )	Positive	29 Jan 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis